Reglan

Gastroparesis, Aerophagy, Migraine + 23 more
Treatment
4 FDA approvals
20 Active Studies for Reglan

What is Reglan

MetoclopramideThe Generic name of this drug
Treatment SummaryMetoclopramide is a medication used to treat nausea and vomiting caused by diabetic gastroparesis and gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain medical procedures. It does not increase stomach acid production, and is available in a tablet form or as a solution or intravenous injection. Metoclopramide was approved by the FDA in 1980.
Metoclopramideis the brand name
image of different drug pills on a surface
Reglan Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Metoclopramide
Metoclopramide
1985
199

Approved as Treatment by the FDA

Metoclopramide, commonly known as Metoclopramide, is approved by the FDA for 4 uses including Gastroesophageal reflux disease and Gastroesophageal Reflux Disease (GERD) .
Gastroesophageal reflux disease
Gastroesophageal Reflux Disease (GERD)
Failed conventional therapy
Gastroparesis

Effectiveness

How Reglan Affects PatientsMetoclopramide helps your stomach empty faster by relaxing the muscle at the bottom of your esophagus. It also helps to reduce nausea and vomiting. Additionally, it helps your gastrointestinal tract move without increasing the amount of acid or digestive juices. However, if taken for more than twelve weeks, it can cause unwanted symptoms such as tardive dyskinesia, dystonia, and akathisia.
How Reglan works in the bodyMetoclopramide is an antiemetic and prokinetic drug. It helps reduce nausea and vomiting by blocking dopamine and serotonin signals in the brain, and it helps food move through the digestive system by blocking dopamine signals in the muscles. It also helps increase the activity of a key muscle in the digestive system, allowing food to pass through faster.

When to interrupt dosage

The advocated dosage of Reglan is determined by the diagnosed state, including Nausea, Intubation (procedure) and Gastroesophageal Reflux Disease (GERD). The amount of dosage is contingent upon the administration method (e.g. Spray or Tablet, orally disintegrating) stipulated in the table hereunder.
Condition
Dosage
Administration
Nausea
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
gastric emptying for radiologic procedures
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Therapeutic procedure
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Gastric Motility Disorder
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
prophylaxis of Hiccups
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
meteorism
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Nausea
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Failed conventional therapy
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Acute Coryza
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Nausea
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Hyperacidity
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
radiation therapy induced nausea and vomiting
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Aerophagy
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Flatulence
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Indigestion
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Gastrointestinal distress
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Hiccup
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Nausea
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Pharmacotherapy
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Intubation (procedure)
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Warnings

Reglan has fourteen countermeasures, so it must not be amalgamated with any of the conditions given in the following table.Reglan Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Metoclopramide may interact with Pulse Frequency
Mechanical Intestinal Obstruction
Do Not Combine
Gastrointestinal Hemorrhage
Do Not Combine
Gastrointestinal Perforation
Do Not Combine
Paraganglioma
Do Not Combine
Tardive Dyskinesia
Do Not Combine
Pharmaceutical Preparations
Do Not Combine
Pheochromocytoma
Do Not Combine
Parkinson's Disease
Do Not Combine
Depression
Do Not Combine
Epilepsy
Do Not Combine
Gastrectomy
Do Not Combine
Dystonia
Do Not Combine
Feeling suicidal (finding)
Do Not Combine
There are 20 known major drug interactions with Reglan.
Common Reglan Drug Interactions
Drug Name
Risk Level
Description
Acepromazine
Major
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine.
Aceprometazine
Major
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Aceprometazine.
Acetophenazine
Major
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetophenazine.
Alimemazine
Major
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Alimemazine.
Amisulpride
Major
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.
Reglan Toxicity & Overdose RiskThe lowest toxic dose of metoclopramide in rats has been found to be 750mg/kg. Overdosing on metoclopramide can lead to drowsiness, confusion, and movement disorders. Medications for Parkinson's disease, anticholinergic drugs, or antihistamines with anticholinergic properties may be used to treat these symptoms. In infants, an overdose can cause seizures, movement disorders and a lethargic state. Methemoglobinemia, a condition where the blood cannot carry enough oxygen, can also occur after a metoclopramide overdose. Methylene blue can be
image of a doctor in a lab doing drug, clinical research

Reglan Novel Uses: Which Conditions Have a Clinical Trial Featuring Reglan?

Currently, 113 clinical trials are being conducted to assess the potential of Reglan to provide therapeutic benefits in Migraine, Nausea and Pharmacotherapy.
Condition
Clinical Trials
Trial Phases
Gastroparesis
15 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Early Phase 1
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Gastric Acid
0 Actively Recruiting
Gastroesophageal Reflux Disease (GERD)
9 Actively Recruiting
Not Applicable, Phase 2
Flatulence
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Indigestion
6 Actively Recruiting
Phase 3, Not Applicable, Phase 2
radiation therapy induced nausea and vomiting
0 Actively Recruiting
Nausea
0 Actively Recruiting
Gastrointestinal distress
9 Actively Recruiting
Phase 2, Early Phase 1, Phase 1, Phase 3, Not Applicable, Phase 4
Hiccup
0 Actively Recruiting
Failed conventional therapy
0 Actively Recruiting
meteorism
0 Actively Recruiting
Nausea
0 Actively Recruiting
Gastric Motility Disorder
0 Actively Recruiting
Aerophagy
0 Actively Recruiting
Intubation (procedure)
0 Actively Recruiting
gastric emptying for radiologic procedures
0 Actively Recruiting
prophylaxis of Hiccups
0 Actively Recruiting

Reglan Reviews: What are patients saying about Reglan?

5Patient Review
11/22/2018
Reglan for Stomach Muscle Paralysis and Decreased Function from Diabetes
I only need to take one dose of this medication per day, as needed, and it effectively controls my nausea.
5Patient Review
5/20/2017
Reglan for Nausea and Vomiting
Diabetic, have been having issues with nausea and vomiting for over a year now. Since being put on this medication, I can finally eat again without feeling full all the time or nauseous. It's great to feel hunger again. Will definitely be continuing use of this drug.
5Patient Review
11/13/2017
Reglan for Stomach Muscle Paralysis and Decreased Function
I was initially worried about the potential side effects of this medication, but it has helped a lot in just two weeks.
1.3Patient Review
8/10/2019
Reglan for Feel Like Throwing Up
Unfortunately, this medication made my muscle spasms worse and also increased my nausea.
1Patient Review
2/10/2018
Reglan for Heartburn
Do not use this medication. I used the generic form and it caused me a great deal of mental and emotional distress, to the point where I had to go on two different medications to get through it. This drug is banned in Europe and Canada for good reason, and it should be taken off the market in the United States as well.
1Patient Review
1/5/2019
Reglan for Nausea and Vomiting
I only took this medication for two days, but it caused me a great deal of distress. I had strange dreams, felt restless and couldn't sleep at all. I also experienced suicidal thoughts, paranoia and anxiety. The trembling and anxiety were so bad that I decided to stop taking the drug. Based on my experience, I would warn others about this dangerous medication.
1Patient Review
2/25/2022
Reglan for Headache caused by Disorder of Cranial Blood Vessels
Do not take this if you have POTS! It had a really adverse effect on my nervous system and caused my heart rate to skyrocket. I met a nurse who said her daughter had a similar reaction. It was scary and I'm still shaken up from it. Please be careful.
1Patient Review
1/26/2020
Reglan for Condition in which Stomach Acid is Pushed Into the Esophagus
I would recommend trying Amitriptyline before using Reglan for an extended period of time.
1Patient Review
1/26/2020
Reglan for Heartburn
I would recommend Amitriptyline over Reglan if you're struggling with nausea that standard antacids haven't been able to touch.
1Patient Review
4/17/2022
Reglan for Nausea and Vomiting
IV administration in hospital for nausea caused me great distress. I felt an overwhelming urge to move and could not stand still. It was one of the worst experiences of my life. This treatment should only be used as a last resort.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about reglan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the most serious side effect of Reglan?

"REGLAN may cause serious side effects, including tardive dyskinesia (TD), which are involuntary, abnormal movements mostly of the face muscles that you cannot control."

Answered by AI

What is Reglan used to treat?

"This medication is used to relieve heartburn that occurs after a meal or during the daytime. It can also help healing by reducing the damage done by stomach acid to the esophagus. Metoclopramide is also used in diabetic patients who have poor emptying of their stomachs (gastroparesis)."

Answered by AI

What symptoms does Reglan treat?

"Metoclopramide, marketed under the brand name Reglan, is a dopamine antagonist used as an antiemetic to treat nausea, vomiting, loss of appetite, heartburn, and early satiety. Metoclopramide is available in generic form."

Answered by AI

Is Reglan an appetite stimulant?

"This medication works by increasing the movements or contractions of the stomach and intestines. It is used to relieve symptoms such as nausea, vomiting, heartburn, a feeling of fullness after meals, and loss of appetite. Metoclopramide may also be used to treat heartburn for patients with gastroesophageal reflux disease (GERD)."

Answered by AI

Clinical Trials for Reglan

Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Image of University of the Fraser Valley in Chilliwack, Canada.

Mind-Body App + Movement Program for Chronic Pain

19 - 75
All Sexes
Chilliwack, Canada
The investigators are evaluating the effects of a mind-body mobile application, in combination with a guided movement program, on the experience of chronic pain. Participants meeting the criteria for chronic/persistent pain (confirmed via self-report) will complete an online baseline questionnaire. Eligible participants will take part in an intervention that involves use of a 6-week free trial of a mind-body focused mobile application in combination with virtual asynchronous audio-guided somatic education sessions (gentle movement). External data from a usual care control arm and a mobile-app-only arm from a previous study by the same research team, National Clinical Trials (NCT) registry number NCT05090683, will be used for comparison with the current combined intervention. All participants will complete online surveys at the start of the study and after 6 weeks to measure pain intensity and interference (primary outcomes), mental health outcomes (depression, anxiety, stress), pain-related thoughts (pain catastrophizing), quality of life, and fear of movement (secondary outcomes). From weeks 2 to 6, participants will fill out weekly surveys to track how often they engage with each: the somatic education (gentle movement) program and the mobile app. Participants will also complete a follow-up survey at 12 weeks (6 weeks post-intervention conclusion).
Waitlist Available
Has No Placebo
University of the Fraser ValleyCynthia J Thomson, PhD
Image of Endeavor Health in Evanston, United States.

Autonomic Neural Blockade for Postoperative Symptoms in Bariatric Surgery

18 - 90
All Sexes
Evanston, IL
The purpose of this research is to evaluate if autonomic nerve block (ANB- blocking pain and nausea signals) decreases pain and anti-nausea medication requirements as well as the experience of pain/nausea during the first 72 hours after sleeve gastrectomy or gastric bypass surgery. Participants will be randomly assigned either to the standard of care or the ANB group before surgery. As part of standard of care, in both groups, laparoscopic bariatric surgery will be initiated with local anesthetic injected into the abdominal wall. In the ANB group, participants will be given an additional injection of local anesthetic medication to block nerves on and around the stomach.
Waitlist Available
Has No Placebo
Endeavor HealthHerbert Hedberg, MD
Have you considered Reglan clinical trials? We made a collection of clinical trials featuring Reglan, we think they might fit your search criteria.Go to Trials
Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.
Phase 4
Recruiting
Mount Sinai HospitalJonathan SchimmelPfizer
Image of University of Minnesota in Minneapolis, United States.

Visual Adaptation for Visual Snow

18 - 60
All Sexes
Minneapolis, MN
The goal of this study is to learn more about the brain pathways and activity involved in creating Visual Snow Syndrome (VSS). The main questions it aims to answer are: * Does VSS arise from spontaneous activity in brain pathways? * Where in the brain does the activity contributing to VSS arise? * How does brain activity contribute to VSS? Participants will: 1. Undergo assessments and questionnaires to understand visual and mental symptoms, cognitive, and sensory function. 2. Make visual judgements based on images presented to them both inside and outside a magnetic resonance imaging (MRI) machine. 3. Undergo scanning of their brain while inside of an MRI machine.
Recruiting
Paid Trial
University of MinnesotaMichael-Paul Schallmo, Ph.D.
Have you considered Reglan clinical trials? We made a collection of clinical trials featuring Reglan, we think they might fit your search criteria.Go to Trials
Image of HCA Florida north florida Hospital in Gainesville, United States.

Bupivacaine Injection for Headache

18+
All Sexes
Gainesville, FL
Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.
Phase 3
Waitlist Available
HCA Florida north florida HospitalRobyn Hoelle, MD
Image of The Hospital for Sick Children in Toronto, Canada.

ML-Based Intervention for Vomiting in Pediatric Cancer

Any Age
All Sexes
Toronto, Canada
The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients. The main questions it aims to answer are whether an ML model predicting the risk of vomiting within the next 96 hours will: Primary 1\. Reduce the proportion with any vomiting within the 96-hour window Secondary 1. Reduce the number of vomiting episodes 2. Increase the proportion receiving care pathway-consistent care 3. Impact on number of administrations and costs of antiemetic medications Newly admitted participants will have a ML model predict the risk of vomiting within the next 96 hours according to their medical admission information. The prediction will be made at 8:30 AM following admission. Pharmacists will be charged with bringing information about patients' vomiting risk to the attention of the medical team and implementing interventions.
Recruiting
Has No Placebo
The Hospital for Sick ChildrenSantiago Arciniegas, MSc
Have you considered Reglan clinical trials? We made a collection of clinical trials featuring Reglan, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security